BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/8/2022 7:44:25 AM | Browse: 289 | Download: 709
 |
Received |
|
2022-06-23 12:30 |
|
Peer-Review Started |
|
2022-06-23 12:34 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-08-22 03:03 |
|
Revised |
|
2022-09-01 15:10 |
|
Second Decision |
|
2022-10-17 03:30 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-10-17 07:11 |
|
Articles in Press |
|
2022-10-17 07:11 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-10-27 15:32 |
|
Publish the Manuscript Online |
|
2022-11-08 07:44 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Meng-Ye He, Fei-Fei Yan, Kai-Li Cen and Peng Shen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Meng-Ye He, MD, Doctor, Doctor, Medical oncology, First affiliated hospital,Zhejiang University school of medicine, No.79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. 1511051@zju.edu.cn |
| Key Words |
Intrahepatic cholangiocarcinoma; Programmed cell death protein-1 inhibitor; Paclitaxel; Chemo-immunotherapy; Predictive biomarker; Case report |
| Core Tip |
The first-line standard treatment for advanced intrahepatic cholangiocarcinoma has been PD-L1 antibody combined with GemCis therapy, but the median overall survival time still could not break 1 year. However, this patient achieved cCR after second-line treatment with paclitaxel combined with PD-1 antibody and has survived for more than 32 mo. And we performed genetic testing of tissue specimens and found that this patient was without known predictive biomarkers related to immunotherapy efficacy but with BRCA1, KRAS and NTRK3 mutation, and whether there is a therapeutic efficacy correlation deserves further exploration. |
| Publish Date |
2022-11-08 07:44 |
| Citation |
He MY, Yan FF, Cen KL, Shen P. Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature. World J Clin Cases 2022; 10(32): 11889-11897 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i32/11889.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i32.11889 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
